Search Results - Pascale Fouqueray

  • Showing 1 - 13 results of 13
Refine Results
  1. 1
    Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial

    Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial by Julie Dubourg, Kohjiro Ueki, Jean‐Marie Grouin, Pascale Fouqueray

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes

    Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes by Giovanni Pacini, Andrea Mari, Pascale Fouqueray, Sébastien Bolze, Michael Roden

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

    Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes by Pascale Fouqueray, Xavier Leverve, Éric Fontaine, Mathurin Baquié, Claes B. Wollheim

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

    Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Mul... by Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean‐Marie Grouin, Kohjiro Ueki

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 2): A 52‐week, open‐label, multicentre phase 3 trial

    Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 2): A 52‐w... by Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean‐Marie Grouin, Kohei Kaku

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

    Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action by Sophie Hallakou‐Bozec, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, David E. Moller

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

    Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 3): A randomized, double‐blind, placebo‐controlled phase... by Caroline Reilhac, Julie Dubourg, Carole Thang, Jean‐Marie Grouin, Pascale Fouqueray, Hirotaka Watada

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy by Pascale Fouqueray, Valdis Pīrāgs, Silvio E. Inzucchi, Clifford J. Bailey, Guntram Schernthaner, Michaëla Diamant, Harold E. Lebovitz

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy by Pascale Fouqueray, Valdis Pīrāgs, Michaëla Diamant, Guntram Schernthaner, Harold E. Lebovitz, Silvio E. Inzucchi, Clifford J. Bailey

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration

    Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration by Dominique Détaille, Guillaume Vial, Anne‐Laure Borel, Cécile Cottet-Rouselle, Sophie Hallakou‐Bozec, Sébastien Bolze, Pascale Fouqueray, Éric Fontaine

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

    Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes by Sophie Hallakou‐Bozec, Guillaume Vial, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, Anne‐Laure Borel, Éric Fontaine, David E. Moller

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents

    Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents by Rachel J. Perry, Rebecca Cardone, Max C. Petersen, Dongyan Zhang, Pascale Fouqueray, Sophie Hallakou‐Bozec, Sébastien Bolze, Gerald I. Shulman, Kitt Falk Petersen, Richard G. Kibbey

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

    Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity by Vincent Jacques, Sébastien Bolze, Sophie Hallakou‐Bozec, Anthony W. Czarnik, Ajit S. Divakaruni, Pascale Fouqueray, Anne N. Murphy, Lex H.T. Van der Ploeg, Sheila H. DeWitt

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: